Loading...
Loading...
INMB| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 12.3M |
| Operating I/L | -12.3M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.0M |
| Pretax | -12.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -12.1M |
INmune Bio, Inc. is a clinical-stage immunotherapy company specializing in reprogramming the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's product candidates include INKmune for relapse refractory ovarian carcinoma and high-risk myelodysplastic syndrome, INB03 for hematologic malignancies and solid tumors, and XPro1595 for Alzheimer's disease treatment. INmune Bio, Inc. generates revenue through the development and commercialization of these immunotherapy drugs, leveraging license agreements with Xencor, Inc., Immune Ventures, LLC, University of Pittsburg, and University College London.
